Big pharma, M&A, Pharma

M&A: Watson acquires Uteron Pharma for upto $305 million

Posted on 24 January 2013

Tags: , ,

A M&A deal was agreed and signed by Watson Pharmaceuticals, a big pharma company, with  Uteron Pharma for $150 million in cash up front, and up to $155 million in potential future milestone payments.

In the wake of this m&a deal with Uteron, Watson believes that it will help in the expansion of its  Global Brands pipeline of Women's Health products.  This pipeline includes two potential near term global commercial opportunities in contraception and infertility, and one novel oral contraceptive, projected to launch globally in 2018.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on m&a deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Partnering Deals and Alliances with Big Pharma 

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply